Crystalline organic acid salt of amlodipine
View Patent ↗A novel crystalline organic acid salt of amlodipine having improved physiochemical properties, a preparation method thereof and a pharmaceutical composition comprising the same are provided.
1. A crystalline adipic acid salt of amlodipine, wherein, as measured by X-ray powder diffraction, the crystalline adipic acid salt has X-ray diffraction peaks at angles of at least 10.85°, 13.02°, 15.10°, 16.31°, 18.21°, 21.69°, 23.70°, 26.18°, and 28.74°.
2. The crystalline adipic acid salt of amlodipine of claim 1 , having an X-ray powder diffraction pattern substantially same as shown in FIG. 1 .
3. The crystalline adipic acid salt of amlodipine of claim 1 , having a melting point of 164 to 168° C.
4. The crystalline adipic acid salt of amlodipine of claim 1 , wherein the crystalline adipic acid salt is photostable.
5. A method for preparing a crystalline adipic acid salt of amlodipine, comprising:
reacting amlodipine with an adipic acid in methanol,
wherein, as measured by X-ray powder diffraction, the crystalline adipic acid salt has X-ray diffraction peaks at angles of at least 10.85°, 13.02°, 15.10°, 16.31°, 18.21°, 21.69°, 23.70°, 26.18°, and 28.74°.
6. The method of claim 5 , wherein the crystalline adipic acid salt of amlodipine has an X-ray powder diffraction pattern substantially same as shown in FIG. 1 .
7. The method of claim 5 , wherein the crystalline adipic acid salt of amlodipine has a melting point of 164 to 168° C.
8. The method of claim 5 , wherein the crystalline adipic acid salt of amlodipine is photostable.
9. A pharmaceutical composition for treating ischaemic heart disease or hypertension, comprising the crystalline adipic acid salt of amlodipine claimed in claim 1 in a therapeutically effective amount and a pharmaceutically acceptable diluent or carrier.
10. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is in the form of tablets or capsules.
11. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is in the form of liquids or injections.
12. The pharmaceutical composition of claim 9 , wherein the crystalline adipic acid salt of amlodipine has an X-ray powder diffraction pattern substantially same as shown in FIG. 1 .
13. The pharmaceutical composition of claim 9 , wherein the crystalline adipic acid salt of amlodipine has a melting paint of 164 to 168° C.
14. The pharmaceutical composition of claim 9 , wherein the crystalline adipic acid salt of amlodipine is photostable.
15. The pharmaceutical composition of claim 9 , wherein the therapeutically effective amount of the crystalline adipic acid salt of amlodipine has an amount of 2 to 10 milligrams per day.
16. The pharmaceutical composition of claim 9 , wherein the therapeutically effective amount of the crystalline adipic acid salt of amlodipine has an amount of 3 to 16 milligrams per an unit dosage form.